Figure 1. Prisma Flowchart from the identification to the inclusion.

Table 1. Characteristics of studies included in the review.

Table 1. Characteristics of studies included in the review.

AuthorYearNationalityTypeLevel of EvidenceNumber of PatiensMalesFemalesMean Age (SD) [Range]BMI (kg/m2) (SD) [Range]Cemented DMCPatients at
Follow-UpFollow-up (Months) (SD) [Range]MINORSLanglais2008franceRetrospectiveIV82//72 [65–86]/887936 [24–60]12Philippot2009franceRetrospectiveIV51//68.7 [34–92]/515160.4 (±17.6) [24–112]12Tarasevicius2010SwedenRetrospective comparativeIII42//75 (±10) 42421219Schneider2011FranceRetrospectiveIV96257169.9 [34–95]/967741 (±29) [1–101]11Civinini2012ItalyProspectiveIV24//69 [51.3–82.4]/242439.6 [24–60]14Hailer2012SwedenRetrospectiveIV200////2002002410Pattyn2012BelgiumRetrospectiveIV36162070.4 [46–93]/373616 [6–27]11Mukka2013SwedenRetrospectiveIV34132175.7 [58–90]/343418 [6–36]11Toro-Ibarguen2014SpainRetrospectiveIV14//67.8 [29–90]/141464.810Wegrzyn2014franceProspectiveIV61293267 (±10)26 (±9)616189 (±23) [60–138]10Haen2015FranceRetrospectiveIV64//79.8 (±11.1) [40–95]/664250.412Simian2015FranceRetrospectiveIV47//67.9 (±9.3) [38–90]/474787.6 [60–137]11van Heumen2015The NetherlandsRetrospectiveIV46//67 [32–90]27.2 [16.6–43.0]464629 [12–66]11Carulli C2016ItalyRetrospectiveIV11131875.4 [71–86]/111145.6 [24–84]11Luthra2016OmanRetrospectiveIV63353061 [23–91]/636360 [18–72]11Plummer2016USARetrospectiveIV11//64 (42–87)28.6 [20.8–43.6]111128.8 [24–48]12Hamadouche2017FranceRetrospectiveIV51123971.4 (±11.5) [41.1–91.8]26.4 (±6.5) [17.6–56.6]513098.4 [60–156]10Lebeau2017FranceRetrospectiveIV62204270.5 (±11.1) [36–94]27.2 (±4.8) [19.5–43]626276.8 [60–108]10Mohaddes2017SwedenRetrospective comparativeIII43615428275 (±9)/43643637.220Nabil2017EgyptProspectiveIV12//56.6 [34–63]/12122420Stambough2017USARetrospectiveIV8//60.6 [51–71]/8834.8 [24–63.6]12Bruggemann2018SwedenRetrospective comparativeIII69343567 [35–88]/694458.8 [6–106.8]17Chalmers2018USARetrospectiveIV1861264 [37–81]28 [19–47]181836 [24–60]12Evangelista2018USARetrospectiveIV189962 [30–86]29 [19–37]181636 [25–56]11Hipfl2018GermanyRetrospectiveIV15//70 [42–85]26 [17–38]151547 [25–84]11Kavcic2018SloveniaRetrospectiveIV1744712776.8 [54–98]/17415692.4 [60–120]11Ozden2018TurkeyProspectiveIV1431164.5 [33–89]28.8 (±5.2) [18.7–36.2]151438.1 [24–98]13Rashed2018EgyptProspectiveIV31161566.4 (± 5.9)/32311213Spaans2018The NetherlandsRetrospective comparativeIII96385873.1 (±8.5)26.3 (4.5)1029627.6 [3–84]19Stucinskas2018LithuanianRetrospectiveIV2369615172 (±12)/2362362410Tabori-Jensen2018DenmarkProspective comparativeIII56104676.5 (42–93)/56563619Wegrzyn2018FranceProspectiveIV126487864 (±13)24 (±4)13112633 (±17)12Assi2019LebanonRetrospective comparativeIII1631369.2 (±14.8)/161672.9 (±40.5)20Dikmen2019TurkeyProspectiveIV3032766.1 [33–89]26.8 (±7.2) [19.7–36.2]303042.2 [24.6–75.1]12Fathy2019EgyptProspectiveIV2012866.8 [55–80]/20202414Gabor2019USARetrospectiveIV38182062.7 (±9.7)29.7 (±7.0)383817.910Giunta2019FranceRetrospectiveIV2723468.5 (±8.1) [60–84]/272548 [12–84]12Plummer2019USARetrospectiveIV19//64 [48–81]27.9 [18.5–38]19132412Schmidt-Braekling2019GermanyRetrospectiveIV79245568.5 [41–87]26.8 [18.6–41.5]797163.6 [24–122.4]12Wheelton2019England (UK)RetrospectiveIV54124278 [49–97]/545422.8 [6–60]11de l’Escalopier2020FranceRetrospectiveIII76235871 [31–90]25.2 [17.2–38]766376.8 [36–144]10Lannes2020SwitzerlandRetrospective comparativeIII26151178 (±6) [66–88]/262512 [1–96]19Lavignac2020FranceRetrospectiveIV71276462 (±10.5) [38–88]/717128.2 (±2.9) [0.3–124.8]10Mahmoud2020EgyptProspectiveIV2011965.85 (±5.58) [58–78]/20202414Sayac2020FranceRetrospectiveIV74245070 (±11.3) [34–88]/7739128.4 [25.2–194.4]12Schmidt2020FranceRetrospective comparativeIV59//69 (±13.2) [19–92]26.5 (±5.1) [17–46]595924 [12–141.6]20Tabori-Jensen2020DenmarkProsective randomized trialI29141575 [70–82]28 [23–39]29292424Wegrzyn2020SwitzerlandRetrospectiveIV28171182 [74–93]25 [20–39]282842 [24–60]12Bellova2021GermanyRetrospectiveIV33//78.6 (±7.1) [63–93]/331928.5 (±17.3) [3–64]10Bozon2021franceRetrospective comparativeIII23121167 (±10)24 (±3)2323108 (±12)18Elkhadrawe2021EgyptProspectiveIV31161566.6 (±6.3)/32301213Lamo Espinosa2021SpainRetrospectiveIV68155381.7 (± 6.4)/686849 (±22.6)12Moreta2021SpainRetrospectiveIV10//79.2 [71–87]27.5 [19–34]101042 [24–72]12Rashed2021EgyptProspectiveI31161566.38 [63.9–68.7]/31301223Unter Ecker2021GermanyRetrospectiveIII2169612069 (±9)29 (±7)21621669 [60–110]10Uriarte2021SpainRetrospective comparativeIV44133176.3 (±6.7)25.8 (±4.1)444449.220Totals and proportions 34261018 (37.1%)1729 (62.9%) Mean: 26.8 kg/m234523239 (94.5%)

Table 2. Cemented dual mobility cup: surgical information.

Table 2. Cemented dual mobility cup: surgical information.

AuthorYearCemented DMCPosterior ApproachLateral ApproachAnterior ApproachExtensile ApproachAvantage (Zimmer Biomet)Polarcup (Smith and Nephew)Ecofit (Implantcast)TornierADM (Stryker)MDM (Stryker)Medial Cup (Aston Medical)SaturneTM (Amplitude)Novae (SERF)Symbol Cup DM (Dedienne santé)Quattro (Lepine)Apogee (Biotechni Inc.)ADES (ZimmerBiomet)DMS (SEM)Cement Palacos R+G (Heraeus)CMW Type 3 with Gentamycin (DePuy)Antibiotic-Loaded Cement Simplex (Stryker)GraftAutoGraftAlloGraftSynthetic GraftLanglais2008884000480000008800000000000000Philippot200951////00000000